Congress and the Administration Must Act on Solutions that Have Won Bipartisan Support to Deliver Relief for American Patients and Consumers
For Immediate Release
Contact: Jon Conradi
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today on the reintroduction of the Elijah E. Cummings Lower Drug Costs Now Act (HR3) in the U.S. House of Representatives.
“The reintroduction of HR3 adds to the momentum in Washington for Congress and the administration to deliver on campaign promises to lower prescription drug prices and hold Big Pharma accountable,” said CSRxP executive director Lauren Aronson. “Too many Americans cannot afford their medications as a result of Big Pharma’s price-gouging and anti-competitive practices.”
“Now is the time for the administration and Congress to act and advance reforms contained in HR3 that have won bipartisan support,” Aronson continued. “These include solutions to reform the Medicare Part D program to give Big Pharma significant skin in the game in the catastrophic phase of coverage, cap out-of-pocket costs for seniors and keep drug companies’ price hikes below the rate of inflation.”
Measures contained in HR3 that have won bipartisan and bicameral support include solutions to:
Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.